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impact of TEIs in patients after an acute coronary syndrome (ACS patients) and in
patients with chronic heart failure (CHF patients). We developed multi-state
Markov cycle decision trees where TEIs were compared with no intervention.
Model parameters and outcomes were extracted from a reanalysis of a recent
randomized trial in ACS patients, and from a literature search in CHF patients. For
both models, the study was conducted adopting the health care payer perspective
and time horizon was one year. TEI incremental cost-utility ratios (ICURs) were
expressed in 2011 €/QALY and US $/QALY for ACS and CHF patients, respectively.
Base cases analyses were completed by univariate and probabilistic sensitivity
analyses. RESULTS: TEI was more expensive and less effective than no interven-
tion considering the whole ACS patients population. In the subgroup of ACS pa-
tients with one risk factor and no previous history of ACS, however, the ICUR was
20,343 €/QALY. In this subgroup, the probabilistic sensitivity analysis also indicated
that TEI was not cost-effective in a substantial number of simulated iterations. TEI
was dominant–i.e. less expensive and more effective than no intervention–in the
base-case analysis of CHF patients, with 5448 $ saved per QALY. In the sensitivity
analyses, TEI cost-utility was confirmed in most cases and the cost of readmission
was the most sensitive parameter. CONCLUSIONS: Results illustrate the helpful-
ness of cost-utility modeling for identifying subgroups of patients who should be
targeted by TEIs and which measurements require particular attention in cost-
utility evaluation. Our modeling framework could be helpful for evaluating the
cost-utility of TEIs in other settings.
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OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness of
drugs from 4 classes of antihypertensive medications for use in management of
hypertension in Nigerians without compelling indication to use a particular anti-
hypertensive drug. METHODS: The study employed decision analytic modeling.
Interventions were obtained from a meta-analysis. The Markov process model
calculated clinical outcomes and costs during a life cycle of 30 years of 1000 hyper-
tensive patients stratified by 3 cardiovascular risk groups, under the alternative
intervention scenarios. Quality adjusted life year (QALY) was used to quantify clin-
ical outcome. The average cost of treatment for the 1000 patient was tracked over
theMarkov cyclemodel of the alternative interventions and resultswere presented
in 2010 US Dollars. Probabilistic cost-effectiveness analysis was performed using
Monte Carlo simulation, and results presented as cost-effectiveness acceptability
frontiers. Expected value of perfect information (EVPI) and expected value of pa-
rameter perfect information (EVPPI) analyses were also conducted for the hypo-
thetical population. RESULTS: Thiazide diuretic was themost cost-effective option
across the three cardiovascular risk groups. Calcium channel blocker was the sec-
ond best for Moderate risk and high risk with a willingness to pay of at least
2000$/QALY. The result was robust since it was insensitive to the parameters
alteration. CONCLUSIONS: The result of this study showed that thiazide diuretic
followed by calcium channel blocker could be a feasible strategy in order to ensure
that patients with hypertension are better controlled.
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OBJECTIVES: The evaluation of the utilisation of drugs involved in treatment of
CVD, its consumption in terms of expenditures units and number of packages
prescribedwithin 2008 -2011.METHODS:Analysed datawere abstracted fromState
Institute for Drug Control SR and studied in accordance with financial units (€) and
number of packages prescribed every year. RESULTS: The overall consumption of
drugs involved in tretament of CVD in number of packages prescribedwas increas-
ing from 2008 until 2010. In 2011 very slight decrease can be seen (3,8% from 37 331
100 to 35 913 249). In terms of financial units, the consumption of drugs increased
from 181 319 656,40€ in 2008 to 194 185 283,80€ in 2011(the highest). The most
prescribed ATC group was C09- Renin –Angiotensin System agents (24%, with its
peak in 2010 - 9076 419 packages), in financial view it represents 33% (246 521 428,70
€) of all expeditures on CVD drugs (749 777 407,30 €) . Out of this group, C09A – ACEI
plain was the onemost prescribed with its peak in 2008 (4 820 987 packages, 23 172
192,40€), eventhough its prescription has decreasing tendency (the lowest in 2011
only 4 064 845, 17 262 264,40€). CONCLUSIONS: Obtained data proved that despite
slight decrease in the number of prescribed drugs in 2011, the financial expendi-
tures for cardiovascular medicines increase every year. The most prescribed were
C09 the Renin- Angiotensin System agents – C09AACEI plain, but the expenses had
a decreasing tendency. According to this study, there is no continual proportion
between amount of prescribed medicine and the amount of expenses on CVD.
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OBJECTIVES: It is estimated that over 100 million Americans currently have high
blood pressure, high cholesterol or both, and most of these individuals do not
properly control their conditions. This study assesses the relationships between
employee adherence to both statins and antihypertensives and the short-term
disability costs in a large manufacturing company. METHODS: A retrospective
analysis of pharmacy claims was conducted to identify individuals within a large
manufacturing company who were continuously eligible for a three-year time
frame (between 2001 and 2007) and who received a prescription for both an anti-
hypertensive and a statin during that time. In those cases where an individual’s
eligibility spanned a longer time period, the most recent three-year span was cho-
sen. The resulting sample included both treatment-naïve and treatment-experi-
enced patients.Medical, pharmacy, and short-termdisability costswere calculated
for a one year follow-up. Adherence was measured using proportion of days cov-
ered (PDC), where a PDC80was considered adherent. Multi-variable linear regres-
sion was used to examine the relationships between cost and adherence, control-
ling for patient demographics (age, gender, and job type) and Charlson co-
morbidity score. RESULTS: Among the 10575 individuals in the study, the mean
adherence to these cardiovascular medication classes was 67%, and 46% (N4859)
of the study population had a PDC80. The average total medical/pharmacy costs
were higher for the adherent patients, primarily due to their higher pharmacy
costs. Individuals who were adherent to their cardiovascular medications had
lower short-term disability costs ($1331/year) than did the non-adherent
($1828/year). CONCLUSIONS: In general, patients who were adherent to their sta-
tin/anti-hypertensive drug regimens had lower short-termdisability costs than did
the non-adherent. Employers concerned with the relationship between cardiovas-
cular disease and employee costs should also consider the effect of adherence to
statins and antihypertensives on short-term disability costs.
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OBJECTIVES: Describe health care utilization and costs associated with acromeg-
aly, a rare pituitary disorder that may result in considerable comorbidities and for
which data on US health care costs are limited. METHODS: Retrospective claims
study in a US commercial health plan analyzed adults with an acromegaly-related
diagnosis, procedure, or medication between July 2002 to June 2010. Subjects were
observed for sixmonths before their first acromegaly-related claim and until death
or disenrollment. RESULTS: A totlal of 1056 subjects had mean (SD) age of 42 (17.2)
years on their first acromegaly claim; 49% were male. Common comorbidities in-
cluded hypertension (23.2%), diabetes (14.4%), and arthropathy (14.3%). Most com-
mon specialty office visits included neurology (66.4%), endocrinology (58.2%), and
ophthalmology/optometry (45.8%). A majority of subjects (72.8%) visited a primary
care physician (PCP). Average number of office visits per-year was 4.8 for PCPs, 2.2
for endocrinologists, 1.5 for neurologists, and 0.6 for ophthalmologists/optome-
trists. Proportion with any all-cause and acromegaly-related healthcare utilization
included 99.9% and 96.7% with an ambulatory visit, respectively, 48.6% and 6.8%
with an emergency room visit, and 45.9% and 25.4% with an inpatient admission.
Total all-cause healthcare costs (medicalpharmacy) averaged $2255/per-mem-
ber-per-month. While pharmacy costs comprised 19.1% ($431/2255) of total costs,
ambulatory and inpatient costs comprised the highest proportion of total medical
costs, 48.1% ($877/1,825) and 44.7% ($815/1,825), respectively. Of total all-cause
health care costs, 44.6% was for total acromegaly-related care ($1,005/2,255). Of
total acromegaly-related medical costs, 63.3% ($498/787) was for acromegaly-re-
lated inpatient care. CONCLUSIONS: While acromegaly is generally under-diag-
nosed, subjects in this study had substantial health care utilization and costs for
acromegaly-related care. Subjects visited a PCP most often, suggesting that sub-
stantial diseasemanagementwas provided by physicianswhomay only treat a few
acromegaly patients during theirmedical careers. Future studies focusing on treat-
ment patterns prior to confirmed acromegaly diagnosis may increase awareness
and expedite diagnosis of this condition in an earlier stage.
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OBJECTIVES: To quantify the resource utilization predictors and cost of cardiovas-
cular disease using the Australian Reduction of Atherothrombosis for Continued
Health (REACH) registry. METHODS: This paper describes two-year cost data esti-
mated using a bottom-up costing approach, and presents patterns of resource
utilization based on types of vascular disease. Themultivariate predictors of num-
ber of hospitalization, medication and other health services used per patient and
related costs at two-year follow-upwere examinedusing generalized linearmodels
(GLM). Government reimbursement data from 2011 was used to calculate direct
health care costs. RESULTS: Overall 2873 of the total 68 236 patients in the REACH
registry cohort were enrolled from Australia. The two-year follow-up data was
available for 2856 (99.4%) patients with or at high risk of atherothrombosis. Overall,
the mean (SD) direct expenditure over 24 months of follow-up per person was
$7544 ($10 758). In the adjustedmodel, patients with coronary artery disease (CAD)
and peripheral arterial disease (PAD) incurred A$1255 (95% CI $199 to $2310) and
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A$4942 (95% CI $3509 to $6375) more in mean total costs compared to cerebro-
vascular (CerVD) patients respectively. A history of atrial fibrillation (AF), PAD and
diabeteswas associatedwith higher resource utilization.CONCLUSIONS:Our anal-
ysis has found that significant predictors of resource utilization and medical costs
were PAD, AF, and diabetes. The results highlight the need for policies that target
reducing the number of co-morbidities, which will decrease the incidence of PAD,
AF and diabetes in population, given current and projected burden. This data pro-
vide the necessary framework for economic evaluations of health interventions.
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OBJECTIVES: There are few large trials devoted to atrial fibrillation (AF) manage-
ment in the acute care setting, and no standardized strategy in place. METHODS:
RHYTHM-AF is a prospective observational study fielded in 10 countries. Patients
considered for cardioversion (electrical, ECV or pharmacological, PCV) were en-
rolled betweenMay 2010 and April 2011 (n 3397). We comparedmedical resource
(MR) and median lengths of stay (LoS) calculated as discharge minus admission
time. RESULTS: Patients’ serum haemoglobin and creatinine were measured most
frequently in Spain (99.4% and 99.0%) and least in the Netherlands (49.7% and
96.7%). Thyroid hormone levels were most often available in Germany (78.6%) and
least in Spain (7.3%). Italy, France, Poland and UK performed transthoracic echo-
cardiography commonly (55.5%, 67.7%, 72.1% and 70.4% respectively). Transoe-
sophageal echocardiography was rarely administered, except in Germany (73.1%).
Chest X-ray also varied from 95.2% (Spain) to 8.9% (Sweden). LoS varied by region
andmode of CV. Australia (66% ECV), the Netherlands (77 %), Sweden (96%) and UK
(85%) had LoS  24 hrs. Among those whose primary mode of cardioversion was
ECV, the LoS was highest in Poland (51% ECV) at a median of 54 hours, in Germany
(91%) at 53 hours and in France (81%) at 46 hrs. Among those on PCV, France (20%)
and Australia (35%) had the highest LoS at 192 and 140 hrs, respectively; the Neth-
erlands (23%) and Spain (79%) the lowest, at 5 and 10 hrs. CONCLUSIONS: There is
regional variability in MR and LoS among AF patients. Several patient-, physician-
,and/or environmental- level factors may contribute to this variation. Further re-
search examining factors which may contribute to and result from extensive hos-
pital stays and diagnostic procedures and to assess whether the variability of these
are associatedwith one another iswarranted to further inform clinical practice and
quality of care.
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OBJECTIVES: To examine how cost sharing for prescription drugs affects compli-
ance with antiplatelet therapy and subsequent health outcomes among patients
with acute coronary syndrome (ACS). METHODS: A retrospective outcomes study
using administrative data from medical and pharmaceutical claims of patients
enrolled at health plans offered by 26 large employers drawn from all regions of the
country. A total of 14,325 patients were diagnosed as having ACS and underwent
coronary stent implantation between 2002 and 2005. Each patient was followed up
for a maximum of 2 years. Primary outcomes measures were adoption of outpa-
tient antiplatelet therapy, adherence to outpatient therapy, hospital admissions,
and healthcare expenditures. RESULTS: Patients with ACS who face higher coin-
surance are less likely to adopt outpatient antiplatelet therapy within the first
month after stent implantation and aremore likely to discontinue treatment in the
first year after stent implantation (P 0.01). Higher coinsurance is also associated
with an increased number of ACS rehospitalizations (P 0.01). For patients in
health plans with higher coinsurance rates, expected costs from ACS hospitaliza-
tions are $2796 (38%) higher in the first year after stent implantation (P 0.01).
CONCLUSIONS: Higher copayments for prescription drugs are associated with
lower utilization of antiplatelet therapy and with higher likelihood of rehospital-
ization among patients with ACS. As a consequence, total healthcare spending for
patients with ACS increases by approximately $615 in the first year after stent
implantation.
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OBJECTIVES: Dysphagia is a frequent complication occurring after stroke as a con-
sequence of neurologic lesions at stake in controlling swallowing reflexes. Unman-
aged dysphagia has been associated with an increased risk of aspiration pneumo-
nia and evenmortality. Alongsidemorbi-mortality, dysphagia has also been shown
to increase inpatient length of stay. This often leads to incremental inpatient costs
of care directly or through its complications. This study aimed at gathering unit
costs related to dysphagia for stroke patients. METHODS: A combined literature
and expert-based costing study was carried out for the following dysphagia cost
items: screening, severity staging, rehabilitation and pulmonary complications.
These costs were primarily estimated based on medical fees and technical proce-
dures billing. 2011 US unit costs and charges according to Medicare perspective
were estimated. RESULTS: Early bedside screening and Speech Language Patholo-
gist (SLP) based clinical assessment ranged between USD 16-26 and USD 40-105
respectively. Instrumental severity staging by either Videofluoroscopy, or Fiberop-
tic Endoscopic Evaluation (with sensory testing or not) was estimated to fall be-
tween USD 331-348. Swallowing disorder rehabilitative sessionmediated by an SLP
is charged aroundUSD 94. Inpatient costs related to aspiration pneumonia second-
ary to post-stroke dysphagia were estimated to range between USD 19,509 - 22,714.
CONCLUSIONS: This study demonstrated the potential economic benefits of any
intervention aiming at reducing the risk of aspiration when considering the high
costs of associated pneumonia.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES:The objective of this studywas to determine the prevalence of patient
behavioral segments and medication adherence levels by segment for a hyperten-
sive patient population. METHODS: Members from MediGuard.org and other on-
line patient panels in the UK, Germany, Italy, and Spain were invited to participate
in aweb-based survey that included: a patient segmentation instrument developed
by CoMac Analytics based on a linguistic analysis of patient talk and the MARS-5
adherence instrument. Subjects were screened to have a diagnosis of hypertension
and treatment with at least one anti-hypertensive agent. RESULTS: 353 patients
completed the on-line survey in August/September 2011 and were categorized
against three different behavioral domains: control orientation [176 (50%)
Iinternal, 177 (50%) Eexternal], emotion [100 (28%) Ppositive, 253 (72%)
Nnegative], and agency or ability to act on choices [227 (64%) Hhigh agency, 126
(36%) Llow agency]. Domains were grouped into 8 different clusters with EPH and
IPH arising as the most common (88 respondents (25%) in each cluster). The prev-
alence of other behavior clusters ranged from 6% (22 respondents, INH) to 12% (41
respondents, IPL). The proportion of patients defined as adherent (scored 25 on
MARS-5) varied sharply across the segments: 51% adherent (45 of 88 respondents)
for the IPH vs. 8% adherent (2 of 25 respondents) classified as INL. Side effects, being
employed, and stopping medicine because the patient got better were all signifi-
cant determinants of adherence in a probit regression model. CONCLUSIONS: By
categorizing patients into worldview segments, we identified wide differences in
adherence that can be used to prioritize interventions and to customize adherence
messages.
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OBJECTIVES: To examine statin adherence and LDL-C targeted treatment goals
(TTGs) among TRICARE beneficiaries receiving treatment for secondary prevention
of coronary heart disease (CHD) at US Military Treatment Facilities (MTFs).
METHODS: Retrospective cohort database study examining TRICARE beneficiaries
18-75 years of age, receiving medical services for a primary CHD event at an MTF
between Jan-1-2004 and Dec-31-2008. Of the 20,658 MTF patients receiving statin-
therapy for CHD, 3,676 had an LDL-C value recorded during subsequent 6-month
(M6), 12-month (M12) and 18-month (M18) periods. TTGswere defined usingATPIII-
NCEP Guidelines (i.e., LDL-C value100mg/dL). Drug adherence was measured us-
ing the Medication Possession Ratio (MPR) at M6,M12, and M18. Persistence was
measured as time to 35-day refill gap. Covariates included age, gender, benefi-
ciary status, comorbidities, statin switching, dosage titrations and other lipid low-
ering therapies. Logistic and Cox regressions were conducted to assess predictors
of TTG and adherence/persistence. RESULTS:The CHD cohortwas 75%male,mean
age 58.8 (SD9.3) years. The percent of patients adherent (MPR0.80) with statin-
therapy was 85% at M6, 79% at M12, and 78% at M18. Older diabetic patients were
more adherent and at TTG. Adjusting for covariates, adherent patients were more
likely to be at TTG in M6,M12, and M18 (OR1.98[1.62-2.42], 2.69[2.25-3.22], and
2.93[2.44-3.52], respectively). Overall mean persistence to statins was 330 (SD199)
days. Approximately 68% of patients were persistent at M6, 50% at M12, and 37% at
M18. Patients at TTGwere less likely to experience a gap in therapy at M6,M12, and
M18 (HR0.83[0.78-0.89],0.80[0.76-0.84], and 0.80[0.77-0.84]). CONCLUSIONS: This
study showed a positive link between statin adherence andTTGs among secondary
prevention patients with frequent LDL-C monitoring in the MHS. Patients with
better adherence to statin-therapy were more likely to be at TTG, compared to
non-adherent patients. Further study is needed to assess generalizability to all
MHS secondary prevention patients.
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